Two Men Charged in a Transnational Counterfeit Semaglutide Ring

A federal grand jury in Florida has charged two men with running a smuggling ring that supplied counterfeit versions of Novo Nordisk's injectable semaglutide to U.S. drug distributors for nearly a year, complete with fake packaging, fake pen labels and fake needles built to pass as the real manufacturer's product.

According to the Department of Justice, Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, obtained the counterfeit injectable semaglutide from unauthorized manufacturers in China and sold it to U.S. distributors at deeply discounted prices between July 2023 and April 2024. Each is charged with one count of conspiracy to commit smuggling and defraud the United States, three counts of smuggling, and two counts of selling and holding counterfeit drugs for sale — a combined maximum of 71 years in prison apiece, if convicted. Roy was arrested on an INTERPOL Red Notice and extradited from Italy; both made their initial appearance in federal court in Tampa.

What the charges describe

The indictment's details are specific about packaging, not about chemistry. Prosecutors say the counterfeit product used fake package inserts, fake pen labels and fake needles designed so a downstream buyer would believe they were handling the real manufacturer's branded pen. The FDA's Office of Criminal Investigations, which worked the case with federal prosecutors, says the scheme continued even after the agency seized a shipment and issued a public warning about it in December 2023 — meaning the ring kept selling for another four months with a known federal warning already on the record. Acting FDA Commissioner Kyle Diamantas put the agency's concern plainly: "Infiltrating the American drug supply with counterfeit products isn't just a crime — it's also a direct threat to public health." Assistant Attorney General A. Tysen Duva was blunter about motive: "These defendants allegedly exploited people's health to pay themselves." Fox 13 Tampa Bay and other local outlets independently confirmed the charges and penalties from the same court filing. As with any indictment, the allegations are unproven and both defendants are presumed innocent unless and until convicted.

Why a fake peptide pen is a harder problem than a fake pill

A counterfeit tablet is, chemically, a simpler thing to fake badly: press some filler into a pill shape, print a logo, and the fraud is at least inert. An injectable peptide hormone is a different kind of object. Semaglutide is a 31-amino-acid peptide with a fatty-acid side chain attached specifically to slow its breakdown in the body; getting that right requires the correct amino acid sequence, the correct attachment chemistry, and a sterile liquid formulation held at the correct concentration, typically delivered through a pen built to dose it precisely. None of that is verifiable by looking at a label, a needle or a pen casing — which is exactly the part counterfeiters in this case are accused of getting right. What's inside a counterfeit unit, by contrast, is unconstrained: it could be the real peptide at the wrong strength, a degraded or misfolded version of it, an entirely different substance, or nothing active at all, packed under non-sterile conditions no regulator has inspected. The only way to know is to test the contents against a reference standard in a lab — not to examine the packaging, however convincing the needles are.

What is known, and what isn't

Known: the defendants, the specific charges, the roughly nine-month window of alleged activity, the extradition, and the fact that the FDA's own December 2023 warning didn't stop the scheme at the time. Those are matters of public court record.

Unknown, at least from what prosecutors have made public so far: what the counterfeit units actually contained. Neither the Justice Department's announcement nor the FDA's names a lab result, a contamination finding, or a reported patient injury tied to this specific ring — which is a narrower claim than some other counterfeit-peptide cases that have surfaced this year, and worth not overstating. Also unknown: how many units reached which distributors, how many patients may have received them, and how much money changed hands. An indictment states what the government intends to prove, not a completed accounting of the scheme's reach.

What this means for researchers

This case sits downstream of a dynamic this journal covered in September: a fast-growing, largely unregulated market for peptide products, where blockchain analytics firms have tracked a roughly twenty-five-fold rise in cryptocurrency payments to peptide vendors in two years. A criminal indictment over a widely prescribed, FDA-approved peptide hormone is a reminder that the provenance problem isn't confined to obscure research compounds sold on anonymous storefronts — it reaches branded, approved drugs moving through ordinary-looking distribution channels, well after approval has supposedly settled the safety question.

The practical issue for anyone sourcing peptide material, approved or investigational, is the same one this case illustrates: packaging authenticity and chemical identity are two separate questions, and only one of them can be faked convincingly by copying a label. The other requires a specific, checkable answer — a lot number, a named laboratory, a dated analysis — that either exists for a given unit or doesn't. Prosecutors allege Roy and Ramancha built a very good answer to the first question. Nothing in the record says anyone had an answer to the second.

That gap is likely to keep generating cases like this one as long as the price difference between legitimate and counterfeit channels stays large enough to make smuggling worthwhile. Whether courts and regulators can close it faster than new supply opens up is, at this point, an open question the next several prosecutions will help answer.